Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Arnold, the clerk didn't address that ... she just said that the Judge had called in and told her to pass it ... I think this is a victory for CYGX, but can't say for sure. I haven't read the rules for this court.
I tried to ask that but the clerk was speaking legaleze and I was talking civilianeze ... LOLOL. I think that she meant that after the 28th of this month, the action will be cancelled as a 'matter of law.'
by time constraints...do you meant the case will not be re-opened at all? or just today? TIA
I just spoke to the clerk and she told me that nothing was ruled this morning ... it was passed over and that the time constraints are almost expired so in all probability there will be no further action. However, she said that it could change but she did not feel that it is likely. Sorry that I wasn't able to attend this morning, but the Katy Freeway was a little too crowded and I have a very full slate at the moment.
Arnold. do you have a link to that info?
Right you are Sanoman. In the last session of the legislature there was a bill to construct a battery of wind-powered turbines just outside the Capitol. It had been determined that the quantity and velocity of hot air available could probably power the entire state ... especially when the legislature was in session. Unfortunately, nobody could come up with an appropriate way to tax the electricity thus generated so it was referred to a committee and will not see the light of day.
Good Job TK, that explains why Yen, Harrilyn and XX always have a big smile on their face ... they have been sampling the products .... as usual, you managed to bring more than a slight chuckle ... hey, want to come down and I'll call my old classmate Dick and we can go quail hunting ....
A full explanation would take volumes and I'd no doubt get things tangled up, but as I recall, Mike wanted to pursue other ideas. Remember, he and Charlie Conrad had developed the concept that led to the first issued patent. Mike had been forced into the top job upon the death of Lawrence Mealey. Lawrence was indeed an internationally known and respected (sometimes hated) top executive.
Mike has an IQ that is somewhere in the stratosphere and he just doesn't think like most of us. He also is not the type to be tied to a desk and a position that requires budgeting and all of the politically correct words and deeds. I think he fully understands and accepts his limitations. Also, Mike just isn't consumed with things like money.
There were some other considerations in him naming both Malcolm and Lawrence to their jobs, but they probably are best not addressed herein.
Hope that helps.
Paulness, you have no idea why Mike turned over the helm to others, now do you? Are you so paranoid that you think everyone who has been involved in any manner with CYGX has some kind of nefarious agenda? That is simply not true. As a matter of fact, you'd have to say that everyone who consistently posts only positively also has an agenda .... now wouldn't you. Try to be a little fair.
Good afternoon HC ... surely you have to be joking ...
The CFO, who came on board earlier, left Wall Street in a daring move of entrepreneurial risk taking and has demonstrated that kind of high spirit despite the many setbacks through the years.
LW was a struggling somewhat new stock broker when Mike brought him on board to help with some sales of private placements. He wasn't a 'Wall Streeter' ... he was just like a few thousand others here in Houston. I know because I had an account with him. He did okay .... he bought whatever I told him to buy and sold whatever I told him to sell and charged his little commissions. The reason I retained him is that Dell Gibson and Mike Skillern used him. Believe me, LW did not 'step down' when he came on board with CYGX. And you don't even want to get into his 'vast' private business exprience.
Now, Malcolm has been at the helm for a while and has indeed overseen a lot of the advances in the science, but ...
this endeavor (in which we all participate tangentially as shareholders) is the creative brainchild of this man and his close associates.
... is just a little bit of a stretch. This was the brainchild of Mike Skillern. And yes, we were lucky to have Malcolm around.
I'm not trying to pick on you, but I'd prefer to see such glowing praise at least kept in perspective.
Wow Arnold, those Ramblin Wrecks sure know how to write some good PR's that get right to the meat of things, don't they .... wonder if they still have Prof. Battle teaching solid state theory at the FG campus ... wonder if he has forgiven me for leaving that charged up electrolytic capacitor on his desk .... ROFL
ROFLMAO ... you are still one of my favorites here. We've been at this for a long, long time, haven't we. Isn't this our fifth or sixth board? LOL
Have a great day .....
Ellen, that was the impression that some of the RBW's had left on me. I thought that we were in fully scale production, but if that were the case, why would Frank be dodging questions.
Hogger ... aren't they using it now for their own purposes??? Or am I remembering an incorrect post? If so, doesn't that mean that they are in fact manufacturing it ... even if it is in small amounts for themselves???
Of course, if we have the manufacturing capability, then why haven't we been progressing the testing of actual products? This is making less sense every day. I just can't see any reason for anything less than a straight clear concise answer to the questions that were asked unless there is a need for plausible deniability of culpability. Can you give any valid reason for such evasive answers?
That is not what we have been wanting to hear.
Actually about 3 weeks ago I stopped in to the Cytogenix offices and talked to Mr. Vazquez and asked if the prototype worked. His exact answer was basically "it would be disingenous to put out a PR that wasn't true". Again a good sidestep.
What I also found interesting was I asked what was the regulatory process to get SynDNA approved for use. He refused to answer this question. I told him I felt this should be public information and was just asking in general the process but he would not budge.
Maybe our resident RBW's can get some straight answers ... how about it PaulNESS, gdpec or Scooby? The question is, do we have the capability to manufacture synDNA right now and if so are we doing it and if not WHY NOT?
NEWS FROM HOUSTON!!!!!!!!
It has been determined that the Houston Texans will not be playing in Superbowl XL.
Bet that got some folks attention .... LOLOL (Sorry, but I just couldn't resist.)
John, you make it sound like I am a basher of the nth degree and that everytime I get my paws on something negative, I mount a crusade. I have been a booster of this stock for many, many years, but back when I was the only one defending against real basher attacks (and you remember those were by pro's) I always stated that I detested the acts of the hypsters (and you remember when we had some real pro's there, also) just as much as I did the bashers. Still feel exactly the same.
I have made some great money on this stock ... Yes, I still have stock in good old CYGX and so do several in my family.
We have been very close to some of the events that have shaped the corporation. I think I have been very responsible and restrained in NOT posting everything I have witnessed ... good and bad.
Last month Malcolm chastised me during a conversation for some of my posts and in some of what he said, he may have been right, but from my first hand information, I believe we should be much further along. Maybe sometime I'll expand on that, but not now.
TK, that is a great one ... I'll be chuckling about it for a while ... you are one of the very few who understands what the "hogger" is all about. I actually have a caricature (sp?) that is very similar .... good job. ROFLMAO
Of course not BigB ... we're enjoying a sip of Scapa to celebrate the big jump. It's just that PaulNESS hit a nerve that has bothered me for many, many years. Volume and price both shoot up and then here comes a PR. That does raise a few eyebrows and when he talks about insider trading, it really makes me cringe. I;d love to see some real news hit the wires ... we've certainly waited for it ... I just would hate to think that the news had been leaked out to folks on the "A" list and not to the rest of us ... that's not real kosher, I don't think.
I don't know ... you were the one saying that insiders were buying before you said that no they weren't ... and anyway, they have enough stock options to last a whole bunch of us a lifetime, don't they? Uh, why did you specifically mention insiders buying if you really don't think they were? You are a little difficult to understand sometimes. You don't really think anybody leaked anything, now do you?
Okay ... then you didn't really mean what you wrote ... do I have it right now? There weren't really any insiders buying after all ... uh, is that what you are saying? It was just some folks who happened to hear the leaked news ... uh, is that right now?
I think very BIG NEWS is coming and the insiders are buying.
Paulness, do I understand you correctly?Are you accusing some folks of insider trading? That always seems to be the case just before news is released to the public and other stockholders. Do you think this needs to be investigated further? I think you and a couple of others have mentioned it before.
I think very BIG NEWS is comming and the insiders are buying.
With this little disclaimer, how can anyone term anything released by Dutton as NEWS? You can rattle on for hours about how Dutton maintains an objective stance, but when someone is paying the amount that CYGX pays for those release, then it is propaganda ... plain and simple.
The cost of enrollment in our one-year continuing research program is US $33,000 prepaid before commencement of our research activities. We received $47,000 from the Company for 8 reports and requisite Research Notes commencing 7/17/2002, and do not accept payment of our fees in company stock
Well, that's what my L2 says ... of course it has been known to be off ... lolol
Vaccine Promising Broad Protection Against Bird Flu Nears Human Testing
Monday, January 30, 2006
A new bird flu vaccine promises broad protection against bird flu -- even if the virus mutates.
In animal tests, the genetically engineered vaccine protects chickens and mice against the deadly H5N1 bird flu virus, the strain that has killed people in Asia and Europe.
Human safety tests are poised to start in just a few months, says University of Pittsburgh researcher Andrea Gambotto, MD.
"We are ready to go," Gambotto tells WebMD. "We are ready to start production of vaccine for human trials. In a couple of days, we expect to hear from the federal government about funding for clinical production. Four to six months after that, we can begin human trials."
Vaccines and Virus Mutations
It's not your dad's flu vaccine. Normal flu vaccines -- including the bird flu vaccine now in limited production -- are made from inactivated flu virus grown in hens' eggs. It's a tried-and-true technology that's been around for decades.
But inactivated flu vaccines work only against the exact virus strain they are made from. If a flu virus mutates even slightly -- what experts call genetic "drift" -- the vaccine won't work. That's why the seasonal flu vaccine has to be changed every year or so.
Also, it takes longer to grow vaccine viruses in eggs than it does to grow them with more modern cell-culture techniques. And in the case of bird flu, to which humans have no pre-existing immunity, vaccine protection may take at least two shots given weeks apart.
How the New Approach Works
Gambotto's team uses a different approach. Instead of making a vaccine from pieces of killed virus, the researchers use a common cold virus -- adenovirus -- genetically engineered to carry bird flu DNA. When given by nose spray or injection, these vaccine viruses infect human cells. They go through a single round of replication, during which they "express" pieces of bird flu virus.
These pieces of bird flu virus do two things. One is to stimulate production of antiflu antibodies. These antibodies quickly form a first line of defense against flu infection and disease.
The second thing they do -- something the current inactivated vaccine does not do -- is stimulate antiflu T-cell immunity. This long-lasting form of immunity offers a second line of defense. And it may offer protection against drift variants of the virus used in the vaccine.
"In humans, the H5N1 bird flu takes about two weeks to kill, so there is time for T cells to come out and give protection," Gambotto says.
Will It Work?
Adenoviruses induce very powerful immune responses, says flu expert John Treanor, MD, director of the vaccine and treatment evaluation unit at the University of Rochester in New York.
"Applying this to an H5 bird flu vaccine makes a lot of sense," Treanor tells WebMD. "Gambotto's team shows it can be quite protective in the mouse model. … That is interesting because this could be a pathway toward a more broad-based vaccine that could protect against all viruses in the H5 subtype."
But Treanor warns that lots of vaccine approaches that look promising in mice never turn out to work in men and women. And he notes that experimental adenovirus vaccines have yet to live up to their potential.
"While adenoviruses have been evaluated as potential vaccine vectors for many years, there is no human vaccine that uses adenovirus for a vector," Treanor says. "There is no evidence that an adenoviral vaccine can protect humans against any disease except adenovirus."
Gambotto says this situation soon may change.
"I think this adenovirus technology is like the electric car," Gambotto says. "We all know that sooner or later we will drive an electric car. The technology just isn't quite there yet. But soon we will all be driving one."
Bird Flu Vaccines -- What's Next?
Gambotto says if the adenovirus vaccine works, it could be geared up to full production very soon after a flu pandemic breaks out.
Treanor warns, however, that the time savings offered by new technologies won't resolve all the problems with making a pandemic flu vaccine.
"This is not going to have as big an effect on the time to make a vaccine as you might think," he says. "It is generating the [ingredients needed to produce vaccine], it is the processing time, it is the putting-things-in-vials time, and all the other steps involved in making a vaccine," he says. "Growing a virus is one thing, but not the only thing. A process like this where you clone the gene into something would be faster. You shave time off the growth of the product, but there are other components that would still pose a time barrier."
Treanor hopes that the Gambotto team succeeds. If they don't, it's not the only chance for improved bird flu vaccines.
The next big breakthrough, Treanor predicts, will be finding a way to stretch out vaccine supplies by making small doses more effective. This can be done by giving the vaccine along with a substance called an adjuvant. Treanor says a new adjuvant, called MF59, looks very promising.
And Treanor notes that researchers at the National Institutes of Health are exploring a live-virus bird flu vaccine.
There's already a live-virus vaccine for seasonal flu -- FluMist.
"A development program at NIH is trying to make an H5 version of FluMist," Treanor says. "When we see how effective that is, that could be a big thing."
By Daniel J. DeNoon, reviewed by Louise Chang, MD
SOURCES: Gao, W. Journal of Virology, Feb. 15, 2006; vol 80, online edition. News release, University of Pittsburgh Medical Center. Andrea Gambotto, MD, assistant professor of surgery and molecular genetics & biochemistry, University of Pittsburgh School of Medicine. John Treanor, MD,professor of medicine and director, vaccine and treatment evaluation unit, University of Rochester, N.Y.
Wow, nappy, so you're a legal beagle and all this time I thought you were a Serta perfect Mattress salesman ... I'm impressed.
Anyway, you pretty well stated what I just got from the courthouse ... a motion has been made to reopen. It is not a refiling. The judge might or might not grant the motion. If she doesn't, then it is indeed all over like we thought. If she does grant the motion, then we are back in the ring. I didn't want to wait for hours to get the actual motions, but if I am either bored or just feel the need to sit for hours, I will go back and get them later.
I have been told by another source that the circumstances under which the previous motion to dismiss was granted are being questioned and that there may (or may not) be at least sosme merit to the current motion. Texas has some rather interesting rules concerning the behavior of lawyers and that seems to be at play in this case. I'll keep trying to find out more about those unusual circumstances. This could get interesting ... either way it goes.
BigB, Nappy just contacted me and said he is out of posts for today. If you will drop me an email I'll try to get you together.
Paulness, could you be a little more specific in stating what you are saying? Who is a con man and who is trying to extort?
Give it up napping. Most of the RBW's have absolutely no interest in learning the truth and certainly not the comprehensive overall picture of reality. They indeed just want to hear the good stuff and if there isn't anything good on the winds, then they want to put a spin on inconsequential crappe and pretend that it is earthshaking news. LOLOL
I seem to be hearing a lot of interesting rumors. I hope they are just rumors and that they are a couple of folks wild a$$ guesses and are not founded in fact. However, after reading just a few blasts from the past, I can see that they 'could' have some foundation. I am glad that you have realized that the PP and AVGI crap may play a bigger role than most of us want to think.
In my opinion PP and AVGI are important to follow if you are in this stock. But if the majority of people on this board only want to hear from pumpers, or CYGX's public version of events, I will be glad to do like most on this board and post nothing factual.
Hey Arnold, ever wonder why judges, lawyers, clerks and other of their 'elk' can't simply write things in simple english and say what they mean while meaning what they say .... LOLOL. I may have to be at the courthouse tomorrow on another matter and if so, I'll try to drop by and see if I can get anything definative. I will say that I have been told that the matter is far from being over due to the unusual circumstances that led to the recent actions in the first place.
Have you heard anything that would indicate that the 'pshaw' fiasco was in any manner linked to the current round of legal actions and may be extended to others? I'll be curious to see where all of that nonsense leads. There are just too many things that do not ring true to me ... oh well, maybe that's a result of having lived this long ... rofl.
BTW, we had a business meeting over supper at Yao Mings place last night. The Peiking Duck was great, but I think the curry scallops were the high light for me. Some of our guests from Shanghai had a great time sitting in Yao's chair with their feet dangling just above the floor ... uh, well, my feet were not on the floor either ... those are darned big chairs.
Hey Woody, looks like I missed a fireworks filled weekend. I have family in town from Shanghai for a funeral and we have been meeting ourselves at every turn ... way too busy ... I thought I was supposed to be able to slow down a little when I retired ... LOLOL.
I have just skimmed the posts of the past few days and am amazed that some of the RBW's are defending someone who admitted to at least one felony in his 'mea culpa.' It is even more amazing that they bring up the matter of agenda's and by doing so make their own agenda remarkable apparent. I really hope that there is no connection proven between pshaw and anyone associated with CYGX or this thread.
Now that we have watched the price drop back into the 80's (just like it did last year at this time after a pumped up year end close) I suppose we will get a little break from our resident rah-rah boys telling everyione that they missed the train to the moon - or something equally silly and amiss.
Please Tatankano, no apologies. Your very humorous posts are great comic relief for most of us. Try as I may, I just can't find this political comment you have been accussed of making. It seems to me that the post was more about CYGX and comparing it to the current comedy surrounding the confirmation of a man to the SCOTUS. Please continue to post those parodies ... I take them to be in good taste and very entertaining. Thanks.
I sorry to the board for the lack of OT in my last post. It was late and I was watching the Alito hearings, which inspired me, and I forgot the OT.
Right on TK, and in case anyone wonders just where Frank fits in to this puzzle ...
Sponsored Research Agreements/Collaborations
Sponsored and collaborative research are very effective and economical methods of employing top-notch scientific talent and expensive facilities for a fraction of the cost if we were to replicate these efforts in-house. Sponsored research is paid for by the Company. In collaborative research, one party may provide technology and the collaborating party may use the technology in an investigation. The following is a summary of sponsored and collaborative research projects in progress. The fees charged by the institutions total less than $150,000.
1. Dr. Cy Stein (Albert Einstein Medical School/Montefiore Medical Center) has constructed stable cell lines of melanoma and has used the Company's technology to achieve significant reduction of the Bcl-2 apoptotic gene. Dr. Stein has observed reduced expression at both mRNA and protein levels. The biological analysis of these cell lines has been completed. Dr. Stein will study the effects of CYGX antisense oligonucleotide sequences on cancers transplanted into mice.
2. Dr. Frank Orson (Baylor College of Medicine) is currently conducting an in vivo study to use aerosol delivery of the ssDNA expression vector developed by CYGX targeting pKC-alpha, an oncogene associated with lung cancer. Several variations in delivery methods are being tested including polyethylenimine (PEI) with plasmid IP, naked plasmid ID and PEI aerosol.
3. Dr. Michael Mathis (Louisiana State University Health Science Center) is currently constructing an adenoviral delivery system for CYGX designed single-stranded DNA expression vectors. He will use this system to target eIF4E in head and neck cancer therapy.
4. Drs. Edward Mason and Jesus Vallejo (Texas Children Hospital, Baylor College of Medicine) are investigating CYGX designed Peptide Nucleic Acid compounds as therapeutics for bacterial resistant strains such as Methicillin resistant Staphylococcus aureus (MRSA) and Penicillin resistant Streptococcus using a mouse model.
5. Dr. David Weiner (University of Pennsylvania Medical School) is conducting animal studies using CYGX cell-free produced, synthetic DNA to test the immunological activity of a DNA vaccine against small pox.
6. Under Agreement, CYGX has provided synthetic DNA to a company to test the immunological activity of a DNA vaccine against the Hepatitis B virus.
7. Under Agreement, CYGX has provided synthetic DNA to test the immunological activity of a DNA vaccine against the Influenza virus.
8. The Company licensed a compound from the National Institutes of Health (NIH). This compound will be amplified using the CYGX synthetic DNA production process to make a compound that will be tested by NIH as a DNA vaccine against HIV.
9. Dr. Jeffrey Actor (University of Texas Health Science Center-Houston) has completed a study investigating CYGX designed peptide nucleic acid (PNA) antisense oligomers as therapeutic agents against bacterial infection in a mouse peritonitis model. The PNA treatment was sufficient to rescue up to 100% of animals infected with two different strains of E-coli. This work will be published in the Journal of Antimicrobial Agents and Chemotherapy in August of 2005.
10. Negotiations are being completed for sponsored research to conduct studies to demonstrate proof of biologic activity of the anti-inflammatory compound (CY303)
Does anybody doubt my accuracy in prediction of that stroll across the stage to get their Nobel Prizes ... yea for Yin, Harrilyn, XX and the entire back shop gang .... maybe sooner than even I though it would come ...
Dr. Yin Chen, CytoGenix, Inc. Vice President and Chief Scientific
Officer, commented, "We have completed several animal synDNA(TM)
vaccine studies against different viruses with very promising results.
We are now accelerating our preclinical development of vaccines
designed to protect specifically against various individual influenza
strains, including the H5N1 avian influenza virus."
Here's the story HC ... a little old, but may give a little more perspective to the GE deal ...
Business News - Local News
EXCLUSIVE REPORTS
From the July 9, 2004 print edition
Biotech wave lands on Galveston shore
Galveston snagged two biotech wins last month.
GE Healthcare announced in late June that it has signed on to help Galveston-based AptaMed raise $10 million to research and develop technology for biodefense vaccines. At the same time, AptaMed partner Ciphergen Biosystems of Palo Alto, Calif., announced plans to open a satellite office in Galveston.
Ciphergen and AptaMed became partners as part of a $6 million federal grant through The University of Texas Medical Branch to develop tools for diagnosing infectious diseases.
Ciphergen's Galveston office will be one of several facilities in Texas, including Austin, says AptaMed co-founder and Chairman David Gorenstein. The office will focus on diagnosing viral infections caused by exposure to bioterrorism agents. Gorenstein says Ciphergen has not yet determined how many people it will employ on the island.
Also impressed with AptaMed -- which has received multimillion-dollar research grants from the National Institutes of Health -- is GE Healthcare, a unit of General Electric Co. No stranger to the region, GE Healthcare announced in May it would provide equipment, technology and expertise toward the establishment of a Center for Advanced Diagnostic Imaging in Houston's The University of Texas Research Park.
Gorenstein says GE Healthcare plans to offer AptaMed $1 million worth of consulting to help the firm raise money. GE Healthcare will recover the $1 million only if AptaMed meets its fundraising goal.
Gorenstein believes GE Healthcare's expertise and contacts will help the company turn its patented technologies and research into commercial products.
"GE can tap into pools of money that people in our stage of development would not otherwise be able to access," says Gorenstein, who is also an associate dean of research at UTMB.
Sandy Weinberg, senior director of Fast Trak Vaccines, a division of GE Healthcare, says it is too early to determine what kind of investors will be targeted for AptaMed.
"The first step is a business plan," Weinberg says.
Mary Ann Azevedo
FOR HAPPYCAMPER'S EYES ONLY >>> And my son who is a Ute like Malcolm has a great bet with me as they take on my other Tech today ... go Raiders ... Go Wrecks ...
Although No. 18 Texas Tech and 13th-ranked Alabama both finished 9-2 in the regular season, each achieved their record with very different styles.
Perhaps no postseason matchup offers a greater contrast in opponents than the Jan. 2 Cotton Bowl which pits the high-scoring Red Raiders against the Crimson Tide and their defense-first philosophy.
Texas Tech relies on an explosive offense that averages 511 yards per game, second only to No. 1 USC, while scoring 42.1 points per game - fourth-best in the nation. The Red Raiders led the nation with 403.6 passing yards per game, nearly 20 yards better than the second-place team.
Alabama owns an outstanding defense that limited opponents to 10.7 points per game, more than a point better than any other team. The Crimson Tide allowed the second-fewest total yards (248.3) in the country and the second-fewest passing yards (154.8).
Cotton Bowl chairman Dan Petty admitted these teams were chosen particularly because of their contrasting styles.
''That was part of it, a big part, because that gives the bowl game a special angle that not many other bowl games have this year,'' he said.
Alabama coach Mike Shula knows preparing for Tech's unique offensive system will be difficult.
''We'll be out there and running their plays, but there's no way we can simulate their efficiency and speed,'' Shula said.
Fifth-year senior quarterback Cody Hodges took over this season and helped Texas Tech win its first six games. After a loss to second-ranked Texas, the Red Raiders improved their record to 8-1 and were a candidate for a BCS berth before losing to Oklahoma State on Nov. 12.
Hodges was second in the country with 4,042 passing yards and fourth with 30 touchdowns. Hawaii's Colt Brennan led the nation with 4,301 yards and 35 TD passes.
This is the sixth straight bowl appearance for the Red Raiders under Mike Leach, the first coach in school history to lead the team to three consecutive bowl victories. Tech is one of seven schools nationally to win bowl games each of the past three years.
Alabama makes its NCAA-record 53rd bowl appearance, its seventh visit to the Cotton Bowl and first since 1982 when Bear Bryant's team lost 14-12 to Texas.
''We have heard a lot about it and while you are growing up you hear a lot about Alabama football and the things that they are good at,'' Red Raiders offensive lineman E.J. Whitley said. ''But we are pretty good here, too, and we have some mystique as well. We are pretty excited and pumped up.''
While containing the Red Raiders ' potent offense will be the top priority for Alabama, it must also resurrect an offense that struggled badly late in the season. The Tide opened this season with nine straight wins and were ranked fourth in the nation before losing their last two games to LSU and Auburn.
Quarterback Brodie Croyle was sacked 11 times in a 28-18 loss to rival Auburn on Nov. 19, finishing 13-of-25 for a season-low 109 yards, most of them coming on a late drive.
''We talked shortly after our last game that even though we're feeling pretty down, we've got a lot to be happy about,'' Shula said.
Croyle, a four-year starter, hopes his final collegiate game has a better result. He is the school's all-time leader in several passing categories, including career yards (6,107), completions (469) and touchdown passes (40).
All-American senior linebacker DeMeco Ryans is the anchor of Alabama's defense. A finalist for three major national defensive player awards, Ryans was named SEC defensive player of the year. He played in all 49 games in his career and led the Tide with 69 tackles this season.
Ryans and his defensive teammates will have their hands full against the Red Raiders , who had seven players with more than 300 yards receiving yards this season. By comparison, Alabama had only three players go over 300 yards.
Four players had more than 60 receptions for Tech - Robert Johnson (64), Jarret Hicks (62), Taurean Henderson (62) and Joel Filani (61). Filani led the team with 981 yards while Hicks had a team-best nine receiving TDs. Henderson led the team with 860 rushing yards and 22 total touchdowns.
Alabama will be without cornerback Simeon Castille as it tries to contain Texas Tech's powerful passing attack. The sophomore, who started every game this season and made two interceptions, was ruled academically ineligible under an SEC rule, coach Mike Shula said.
Sophomore Eric Gray and junior Jeffrey Dukes are expected to share time at cornerback in place of Castille.
Alabama's offense revolves mainly around tailback Kenneth Darby , who carried 210 times for 1,161 yards and three touchdowns. Darby had six 100-yard rushing games this season, carrying at least 15 times in all 11 games.
This is the first meeting between these schools.
True, but look at where they are with their testing and product development ... light years ahead of where we are right now. That can (and certainly should) change ... even this year. Hey we're enjoying the feelings of euphoria associated with some very good news after being mushroomed for so long ... let's keep everything in perspective so we don't have a great hangover when we realize that there is still much to be done.
I agree with you also TK, I can't see us dropping below .80, but I can remember when we thought that we would never drop below $2.50.
We will not hit a high plateau and stay there until we actually get a product to market or until our licensee gets a product there. Next week will be a keystone in how much longer that will take. In my meetings and conferences yesterday, some feel that it is realistic to think that at least one product 'could' hit the vet's shelves within six months. I'm not quite that optimistic, but who knows ... the key will be if everyone can act like adults and work together ... we'll see. If they can, we could realistically see $3.00 a share stock this year. If not, we will continue to see a roller coaster ride and everyone spending way too much making their attorneys richer.
Thanx for the info junqmeister ... I didn't present his post with any quarantee of validity ... I just found it interesting and reposted it here. I am very disappointed to hear that he is just another pumper. I was here for the first pump when we saw the share price go to Three bucks and then enter free fall ... guess that is why I am excited but not falling all over myself with the current round of PR's. BTW, I have acquired a very major interest in AVGI so of course I want to see CYGX keep climbing ...
LOL.. sterling is on CYGX? Be warned, he's a crazy pumper
He was a major CMKX tout
his specialty is long ridiculous theories
Wow, look who's back ... good to see you again. Here is a repost from RB ... they usually have such crap over there, but this was a repost that merits an additional reposting ...
By: stervc
28 Dec 2005, 12:36 PM EST
Msg. 292876 of 292987
(This msg. is a reply to 292837 by stervc.)
Jump to msg. #
Some Quick CYGX Thoughts & DD...
Authorized Shares (AS) = 300,000,000
Outstanding Shares (OS) = 119,162,970
Restricted Shares = 44,526,371
Float = 74,636,599
Website for CYGX:
http://www.cytogenix.com/
Website for GE Healthcare:
http://www.gehealthcare.com/usen/index.html
CYGX started out in the molecular medicine arena with their primary product being one to cure Herpes 1 and 2 complexes. Well, Herpes can’t be cured, but it can become stagnant to where it’s placed in a dormant stage.
It was discovered that their product was successful for creating a vaccine for stagnating the spreading of sepsis, which is a condition caused by the presence of microorganisms or their toxins in the tissue or the bloodstream. Sepsis is what causes people to get staff infections in the operating rooms amongst many other fatal things. Sepsis has mortality rates ranging from 30% to 50% and is the most common cause of death in the noncardiac intensive care units.
The department of GE that deals with CYGX, GE Healthcare, is in the Homeland Security arena where they have teamed together to create vaccines. The recent contract with GE is really a multi-million dollar contract that doesn’t have a figure on it because it’s really like a blank check that has been fronted to CYGX to conduct research.
GE Healthcare fronts the cash while CYGX performs all of the research to create vaccines for a variety of potential medicines. The amount of the contract is unknown because of the amount and types of research being unknown until completed.
Since GE Healthcare is a $14 billion unit of General Electric Company (NYSE:GE), it is probably easy to see why money might not be an issue to front this type of research. This will automatically put GE ahead and/or further ahead of all of their competitors in my opinion.
Anti-viral and DNA is needed to be used as a base for running tests for all types of cures and vaccines in the biotech world. CYGX can accommodate companies in this area.
DNA costs $300,000 per gram because of the fermentation process as the bulk of the cost goes toward disposing of dead cells because of the way they have to be disposed of.
CYGX has created a synthetic process where synthetic DNA is created and used to eliminate the need for having a fermentation process. Because of such, this creates huge savings for major biotech companies to perform research.
From these tests, vaccines can now be made. I would like to think that companies on the line of Pfizer and others will eventually want a piece of this technology that CYGX has to offer. This is definitely next generation technology and we are becoming made aware of it before it really kicks off in my opinion. In my opinion, this will be huge!
Currently, CYGX is trading on the OTCBB. I think that the company will steer away from the NASDAQ because of the shorting and naked shorting that the company’s stock could become victim to. It is my understandings that they probably would much rather consider pursuing trading on the AMEX where it’s an auction market. This means that the “Bid” and “Ask” sizes can be reflected more accurately and have less opportunity for any kind of shorting or naked shorting. It will strictly trade on actual and factual “supply versus demand” principles.
From doing my quick DD on CYGX, I had to ignore that the company has a negative EPS and realize that people do buy stocks because of their Earnings, but people buy stocks too because of their “potential” for “future” Earnings. Because of this, I think that CYGX is one of the best mid to long term stocks out there that I think will have an outstanding future. These are only my opinions. I hope this helps!
All is well!
http://www.sterlingsclass.com/
Sterling
Very good TK .. however, you forgot Harilyn .. she has been a moving force in the back shop since the early days ... and she will lead the congo line when they dance across the floor to pick up their Nobels ... Fantastic day. We're breaking our the Scappa and hoping that we don't get any big negative surprises ... there are still a few little lobos that can do some butt-nipping.
TK, you mean it doesn't stand for compulsory Good Manufacturing Practices ... rofl ... we should have started a pool on the exact time we top the buck a share mark.
cGMP